Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jun 1:2:22.
doi: 10.1186/1756-8722-2-22.

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

Shundong Cang  1 , Yuehua Ma, Delong Liu
Affiliations
Review

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

Shundong Cang et al. J Hematol Oncol. .

Abstract

DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders. The first histone deacetylase inhibitor, vorinostat, has been licensed for cutaneous T cell lymphoma treatment. More than 11 new epigenetic agents are in various stages of clinical development for therapy of multiple cancer types. In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical trials for epigenetic therapy of cancer.

PubMed Disclaimer

References

    1. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37–50. - PubMed
    1. Hashimshony T, Zhang J, Keshet I, Bustin M, Cedar H. The role of DNA methylation in setting up chromatin structure during development. Nature Genet. 2003;34:187–192. - PubMed
    1. Cang S, Liu DL. Clinical advances in hypomethylating agents for epigenetic therapy of cancer. Current Cancer Drug Targets submitted and under review. 2009. - PubMed
    1. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26:1351–1356. - PubMed
    1. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs. 2005;14:1497–1511. - PubMed

Publication types

MeSH terms

LinkOut - more resources